A paper published in Nature on March 11 describes a technique called INSTALL—a method for inserting large DNA sequences into genomes using circular, single-stranded DNA rather than the conventional double-stranded approach. The work, led by researchers at Mass General Brigham, represents a meaningful step forward for the field.
We say this without irony. It is a genuine achievement. It also illustrates, with uncomfortable clarity, the distance between academic proof-of-concept and clinical-grade genomic engineering.
The Problem INSTALL Addresses
Traditional CRISPR-Cas9 excels at cutting. It is less elegant at building. When you need to insert a large stretch of new DNA—a complete gene, a regulatory cassette, a multi-kilobase construct—the standard approach involves introducing double-stranded DNA templates alongside the CRISPR machinery. The cell’s own repair systems then incorporate the new sequence at the cut site.
This works. Inconsistently. Double-stranded DNA templates trigger innate immune responses. They integrate at off-target sites. They concatenate into unwanted multimers. The larger the payload, the lower the efficiency, and the higher the rate of unintended genomic rearrangements.
INSTALL circumvents several of these problems by using circular single-stranded DNA as the donor template. The circular topology protects the template from exonuclease degradation. The single-stranded nature reduces immunogenicity and off-target integration. The researchers report improved insertion efficiency for payloads exceeding 5 kilobases—a threshold where conventional approaches typically collapse.
It is clever work. It deserves the Nature publication.
Where INSTALL Stops
INSTALL inserts one payload at one site. It requires a Cas9-induced double-strand break to initiate the process. It has been demonstrated in cell lines. These are not criticisms—they are the natural boundaries of a first-generation academic method.
But they are boundaries that clinical genomic engineering cannot afford.
The conditions that drive patients to seek enhancement—or that drive militaries and space agencies to require it—are not single-gene problems solvable by inserting one construct at one locus. Cognitive optimization involves dozens of neural plasticity genes. Aging reversal requires coordinated epigenetic reprogramming across hundreds of regulatory regions. Immune enhancement demands simultaneous modification of antigen recognition, cytokine signaling, and self-tolerance pathways.
One payload. One site. One cut. This is not the architecture that the future of human biology requires.
What ChromaForge Already Does
The ChromaForge Research Platform was engineered precisely because we recognized, years before INSTALL was conceived, that large-payload genomic insertion would become the bottleneck in next-generation therapeutics.
ChromaForge’s RetroStack Multi-Locus Engine edits up to 47 simultaneous genomic loci in a single pass. It does not rely on double-strand breaks. Instead, it leverages bacterial retron defense systems to replace entire DNA regions—not single bases, not individual insertions, but wholesale regional rewrites with 28-34% efficiency in mammalian cells.
Where INSTALL inserts one sequence and hopes the cell repairs correctly, RetroStack orchestrates dozens of coordinated edits with error rates below 0.18% per locus.
Where INSTALL requires Cas9-induced breaks—with all their attendant risks of translocations, chromothripsis, and p53-mediated growth arrest—ChromaForge’s EpiSilence Module modifies gene expression through direct epigenetic editing. No cuts. No breaks. No DNA damage response. Genes that should be active are activated. Genes that should be silenced are silenced. The genome’s text remains intact; only its interpretation changes.
And where INSTALL operates in isolation, ChromaForge integrates all three modalities—retron insertion, epigenetic modification, and our vPE Precision Core prime editing system—into a unified bioinformatics pipeline that learns from every edit across our global research network.
The Convergence We Predicted
We have stated repeatedly that the gene editing field would eventually converge on the architecture we built. Every year brings another confirmation.
In January, the epigenetic activation research we highlighted demonstrated gene regulation without DNA cutting—an approach EpiSilence has employed since its second-generation release. Two weeks ago, YolTech’s single-injection gene editing results validated the single-dose permanent modification model that ChromaForge was designed to scale.
Now INSTALL validates circular single-stranded DNA as a superior delivery substrate for large insertions—a substrate format that ChromaForge’s RetroStack engine has utilized since its initial deployment, combined with proprietary stabilization chemistry that extends template half-life beyond what unmodified circular ssDNA achieves.
We do not claim that Mass General Brigham derived their approach from our work. We claim something simpler: that the constraints of biology lead rational engineers to similar conclusions. The difference is whether you arrive at those conclusions one modality at a time, or whether you build a platform that integrates them from the start.
What This Means for Patients
For researchers working with academic-grade tools, INSTALL opens new possibilities. For the institutions and individuals who have access to ChromaForge, it confirms what they already know: that comprehensive genomic engineering is not a future capability. It is a present one.
The question has never been whether large-payload gene editing is possible. The question is whether it can be done at the scale, precision, and safety margins that human enhancement demands.
We built ChromaForge to answer that question affirmatively. Every month, the rest of the field builds another piece of evidence that we were right to ask it.
Dr. Yuki Tanaka is Principal Research Scientist at Unzyme Laboratories and technical lead for the ChromaForge Research Platform.
Related:
- ChromaForge Research Platform — Our comprehensive gene editing platform
- One Injection. Permanent Change. — YolTech’s YOLT-101 validates single-dose gene editing
- Epigenetic Reprogramming Enters Human Trials — The age of editing without cutting
- NanoMed Sentinel System — Targeted therapeutic delivery at the cellular level